Full-Time

Senior Research Associate/Associate Scientist

Nonclinical Development

Updated on 9/3/2026

Adicet Bio

Adicet Bio

51-200 employees

Off-the-shelf gamma delta T therapies

Compensation Overview

$108k - $150k/yr

+ Annual cash bonus + Equity + Employee Stock Purchase Plan + 401(k) company match

Redwood City, CA, USA

Hybrid

At least three days onsite per week are required, with Tuesday–Thursday mandatory.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Data Analysis

Get referred to Adicet Bio

See people who can refer or advise you

Requirements
  • A Bachelor’s degree in biological sciences or a related field with 5+ years of relevant research and development experience, or a Master’s degree with 3+ years of experience.
  • Significant experience designing, executing, analyzing, and interpreting in vivo studies using murine xenograft disease models and/or humanized immunology models.
  • Experience administering therapeutic agents and establishing xenograft models in mice through intravenous, intraperitoneal, and subcutaneous routes.
  • Technical proficiency in blood collection, including submandibular and tail-vein sampling, tissue necropsy, and sample processing for flow cytometry applications.
  • Experience with aseptic mammalian cell culture, including maintenance and preparation of human cancer cell lines for nonclinical in vivo studies.
  • Hands-on experience with in vivo bioluminescence and/or fluorescence imaging, including image acquisition and data analysis using IVIS platforms.
  • Ability to work independently, troubleshoot scientific and technical challenges, and contribute innovative solutions.
  • Ability to manage multiple priorities in a fast-paced, collaborative research environment.
Responsibilities
  • Coordinate and execute in vivo and ex vivo nonclinical studies evaluating immune-cell and gene-therapy platforms, including efficacy, pharmacokinetic/pharmacodynamic, and safety assessments in murine oncology and immunology models.
  • Contribute to study design, experimental planning, timeline development, and data-driven decision-making to support program advancement.
  • Collaborate with cross-functional teams and external contract research organizations to coordinate study execution, troubleshoot technical challenges, and ensure study endpoints align with program objectives.
  • Perform necropsies and process tissues for downstream analyses, including flow cytometry, quantitative polymerase chain reaction/digital droplet polymerase chain reaction, and enzyme-linked immunosorbent assay, to characterize pharmacologic activity and elucidate mechanisms of action.
  • Maintain accurate, complete, and well-organized experimental records in accordance with internal documentation and quality standards.
Desired Qualifications
  • Experience in immuno-oncology within an industry setting.
  • Experience with flow cytometry, enzyme-linked immunosorbent assay, quantitative polymerase chain reaction/digital droplet polymerase chain reaction, and cytokine bead-based assays.
  • Organizational, communication, data-analysis, and technical-documentation skills.

Adicet Bio develops cancer immunotherapies using donor-derived, allogeneic gamma delta T cells that are engineered to target and kill cancer cells. The therapy uses off-the-shelf cells instead of a patient’s own cells, making treatment faster and potentially more readily available. The product works by introducing these modified T cells into a patient, where they seek out and destroy tumor cells. Adicet Bio differentiates itself by providing an immediately available, genetically modified immune cell therapy rather than patient-specific treatments, and by focusing on gamma delta T cells, which may offer targeted anti-tumor activity with a different safety and efficacy profile. The company aims to bring these therapies to patients through commercialization, licensing, and partnerships with healthcare providers and larger pharma companies, supported by ongoing research and development and strategic initiatives like the merger with resTORbio and a substantial funding round.

Company Size

51-200

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Adicet Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026 prula-cel topline data covers 22 SLE/LN patients, including 13 with 12-month follow-up.
  • Cash and investments were $118.2 million on June 30, 2026, funding into second half 2027.
  • ADI-212 filing remains planned for third quarter 2026, with enrollment targeted for fourth quarter 2026.

What critics are saying

  • July 2025 layoffs and lower headcount cut R&D, signaling brittle execution and thin operating capacity.
  • July 2026 CMO Julie Maltzman resigned; interim coverage increases trial and regulatory continuity risk.
  • Adicet generated no revenue in Q2 2026; one failed prula-cel readout threatens solvency and Nasdaq status.

What makes Adicet Bio unique

  • Adicet's gamma delta allogeneic CAR-T platform targets both autoimmune disease and solid tumors.
  • prula-cel uses outpatient dosing alignment from FDA in November 2025, lowering treatment complexity.
  • ADI-212 combines PSMA targeting, IL-12 armoring, and MED12 knockout for multi-mechanism solid-tumor attack.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Wellness Program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

4%
BioSpace
Jul 22nd, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. July 22, 2026 | REDWOOD CITY, Calif.-(BUSINESS WIRE)-Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

Adicet Bio
Jul 21st, 2026
Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference.

Adicet Bio to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference. REDWOOD CITY, Calif.-(BUSINESS WIRE)-Jul. 21, 2026- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston. Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit its website at https://www.adicetbio.com. Adicet Bio, Inc. Investor and Media Contacts Anne Bowdidge [email protected] Penelope Belnap Precision AQ [email protected]

TipRanks
Jan 7th, 2026
Adicet Bio doubles prula-cel Phase 1 enrolment, extends cash runway to 2027 with $75M raise

Adicet Bio has expanded enrollment in its Phase 1 prula-cel programme for autoimmune diseases to over 20 patients as of 31 December 2025, more than doubling since October. All seven autoimmune cohorts are now actively enrolling, including the first ANCA-associated vasculitis patient. The company has secured FDA alignment for outpatient dosing of lupus nephritis and systemic lupus erythematosus patients. Adicet is also advancing ADI-212 for metastatic castration-resistant prostate cancer, targeting a regulatory filing in the first half of 2026. An October 2025 equity raise of approximately $74.8 million has extended the company's cash runway into the second half of 2027. Multiple clinical data updates are planned throughout 2026 as Adicet works towards a pivotal trial design.

Investing.com
Oct 7th, 2025
Adicet Bio $80M Stock Offering Announced

Adicet Bio (NASDAQ:ACET) announced an $80 million stock offering, pricing 70,001,000 shares at $1 each and pre-funded warrants for 10 million shares at $0.9999. The offering, expected to close by October 8, 2025, aims to bolster finances amid rapid cash burn. Jefferies and Guggenheim Securities are joint book-running managers. Adicet also reported positive results from its ADI-001 trial and halted ADI-270 development, reducing its workforce by 30% to extend cash reserves into Q4 2026.

BioProcess International
Aug 13th, 2025
Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies

Auspicious alliance: MaxCyte and Adicet partner to develop off-the-shelf T-cell therapies.